aspiring breast oncologist @hopkins_hemeonc, @georgetown IM, former @NIH research fellow, distance runner, @anthropologie enthusiast
Washington, DC
Joined December 2012
- Tweets294
- Following1.1K
- Followers160
- Likes385
Sarah Elizabeth retweeted
One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors
Sarah Elizabeth retweeted
Honored to present our data on neoadjuvant nivolumab and nivolumab/ipilimumab in potentially resectable diffuse pleural mesothelioma (DPM) at #WCLC25. @IASLC
We evaluated perioperative nivo and nivo/ipi in epithelioid or biphasic DPM deemed resectable by multi-D assessment. 1/7
Sarah Elizabeth retweeted
Beyond proud of this incredible, dedicated, brilliant physician/chief fellow/colleague 🤩
Way to go @DenaRhinehart
@Hopkins_HemOnc @hopkinskimmel
Congratulations to Dena Rhinehart, MD, a recipient of the inaugural 2025 AACR-EMD Serono “I’M IN” Oncodisparity Fellowship in Lung and Urothelial Cancers. We look forward to her work on barriers and facilitators to molecular testing for lung cancer in the rural US.
@EMDSerono
Sarah Elizabeth retweeted
A cherished tradition continues! Each year, our new oncology fellows assemble for a photo in front of the iconic Hopkins Dome. Welcome to the new 2025 fellows! @KiarashSalafian @kamarroneMD @NimgaonkarVivek @v_altiery @MarkYarchoan
Sarah Elizabeth retweeted
As we enter spring, your arrival feels even closer! Excited to welcome you soon @PaolaGhanem @jonnypan17 @v_altiery @MetBalev @NimgaonkarVivek @KiarashSalafian
Sarah Elizabeth retweeted
#SABCS24 Preview: A Thursday afternoon panel discussion will highlight genetic variants associated with inherited breast cancer risk. Learn more in SABCS Meeting News:
bit.ly/4gsJYJG
Sarah Elizabeth retweeted
Excited to share our work on immune check point inhibitors related pericardial diseases published in Cardio-Oncology under the mentorship of Dr. @AllanLKleinMD1
@BioMedCentral #CardioOncology @ICOSociety @DocMajid @mdyesilyaprak @Syed_Alveena
cardiooncologyjournal.biomed…
Sarah Elizabeth retweeted
Stay informed with the Pericarditis Alliance! Check out this new study from Cardio-Oncology, Immune checkpoint inhibitors and pericardial disease: a systematic review. cardiooncologyjournal.biomed…
Sarah Elizabeth retweeted
This study found that women with breast cancer who used vaginal estrogen therapy (vaginal creams or vaginal tablets), compared with no hormone replacement therapy use, did not appear to have an increased risk of early breast cancer-specific mortality. ja.ma/47KxDvw
Sarah Elizabeth retweeted
Thank you to @ASH_hematology for inviting me to create the 13th (I think? Maybe 14th) edition of the annual ASH News Daily Hematology Crossword puzzle! #ASH23 (People have liked these enough that I got to do 3 for other societies’ annual meetings this year)
Sarah Elizabeth retweeted
Updated #KATHERINE results #SABCS23
Final IDFS at 8.4 yr median f/u: Risk of recurrence reduced by ~1/2 w/ switch to post-neoadjuvant T-DM1 for those w/ HER2+ EBC & residual disease (abs risk reduction 13.7%) & risk of death reduced by ~1/3 (abs improvement in OS 4.7%). #bcsm /1
Sarah Elizabeth retweeted
2023 was an outstanding year for breast cancer research
As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research.
Looking forward to what is yet to come to improve outcomes for our patients!
@OncoAlert #BCSM
Sarah Elizabeth retweeted
While the OS difference isn’t huge, it’s so important to highlight that side effects of TDM1 are a WHOLE ‘NOTHER LEVEL compared to the newer ADCs! We have definitely gone in the wrong direction when it comes to QoL!
#SABCS23 @SABCSSanAntonio @OncoAlert
Updated results of KATHERINE 7-year fu:
IDFS rates: 80.8% T-DM1 vs 67.1% tras
OS rates: 89.1% T-DM1 vs 84.4% tras
CNS rec: 5% T-DM1 vs 7% tras, looking forward to COMPASS-RD results!
T-DM1 continues to show PFS and OS benefit in pts with RD HER2+ BC
#SABCS23 @OncoAlert
Sarah Elizabeth retweeted
Really interesting and all the way your statistical power is allocated in a trial.
#SABCS23
MONARCH 3 Final Overall Survival: No statistical improvement in OS ❌ but OS was improved by median 13 month favouring abemaciclib arm. Data for ribociclib/MONALEESA-2 shown for comparison OS ✔️. #SABCS23
Sarah Elizabeth retweeted
We strongly support Dr. Stephanie Graff & encourage colleagues in the field of Oncology to support her for @ASCO’s Nominating Committee. #LegorretaCancerCenter @BrownUCancer @ASCO Vote for @ASCO’s elected leadership team at spr.ly/6019uSdnx for a bright future in Oncology.
Sarah Elizabeth retweeted
Dr. Brian Dong of @UofLHealth, @UofLBCC and the @uoflmedschool will present "Update in #breastcancer Genetics and High-Risk Breast Disease" at @uofl Medicine Grand Rounds #PowerofU #cancer #oncology
🕗📅 - 8 a.m. Thursday, Sept. 22
👀💻 - zoom.us/j/91723798423?pwd=c1…
Sarah Elizabeth retweeted
Reading good review articles can shape ideas, help connecting the dots and understanding what’s coming ahead in science.
Here’s 10 review articles that helped me shape my views on breast oncology and drug development:
Sarah Elizabeth retweeted
The largest study to date (N=1.13M❗️) on the prognostic value of HER2-low expression is out on @JAMAOnc. With an HR 0.98 & overlapping OS curves, HER2-low confirms not to be a relevant predictor of prognosis. Congrats to the authors for this huge analysis!
jamanetwork.com/journals/jam…
Sarah Elizabeth retweeted
A short🧵on our podcast @BloodCancerTalk! Our goal is to dissect management of hem malignancies with content experts. We take critical appraisal seriously and hope to bring nuance to discussions. Here are the episodes thus far: tinyurl.com/3vrr752e @AshKishtagari 1/10
Sarah Elizabeth retweeted
CDK4/6 inhibition + endocrine therapy extends post-progression PFS in HR-positive/HER2-negative metastatic #BreastCancer. fal.cn/3pbvc @KalinskyKevin @claudine_isaacs @LombardiCancer @WinshipAtEmory #ASCO22 #ASCODailyNews #BCSM
